Press releaseGlobe Newswire
Benitec Biopharma
BNTC · NASDAQ
$9.04+$0.68 (+8.13%)TodayMarket closed ·
Prev close $8.36
Latest news
- Press releaseGlobe Newswire
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
- Press releaseGlobe Newswire
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
- Press releaseGlobe Newswire
Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
- Press releaseBusiness Wire
PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
- Press releaseBusiness Wire
Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
- Press releaseGlobe Newswire
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)
- Press releaseGlobe Newswire
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
- Press releaseGlobe Newswire
Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference
- Press releaseGlobe Newswire
Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update
- Press releaseGlobe Newswire
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
- Press releaseGlobe Newswire
Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- Press releaseGlobe Newswire
Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301
- Press releaseGlobe Newswire
Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update
- Press releaseGlobe Newswire
Benitec Biopharma Releases Third Quarter 2025 Financial Results
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releaseGlobe Newswire
Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update
- Press releaseGlobe Newswire
Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update
- Press releaseGlobe Newswire
Benitec Biopharma Announces Updated Investor Webcast Information
- Press releaseGlobe Newswire
Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society
- Press releaseGlobe Newswire
Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update
- Press releaseGlobe Newswire
Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.